DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 02 · Volume 43 · March 2010 DOI: 10.1055/s-002-20860

Original Paper

  • 41
    Rettenbacher, M. A.; Hofer, A.; Kemmler, G.; Fleischhacker, W. W.:

    Neutropenia Induced by Second Generation Antipsychotics: A Prospective Investigation

  • 45
    Walderhaug, E.; Kasserman, S.; Aikins, D.; Vojvoda, D.; Nishimura, C.; Neumeister, A.:

    Effects of Duloxetine in Treatment-Refractory Men with Posttraumatic Stress Disorder

  • 50
    Riedel, M.; Spellmann, I.; Schennach-Wolff, R.; Musil, R.; Dehning, S.; Cerovecki, A.; Opgen-Rhein, M.; Matz, J.; Seemüller, F.; Obermeier, M.; Severus, E.; Engel, R. R.; Müller, N.; Möller, H.-J.:

    Effect of Aripiprazole on Cognition in the Treatment of Patients with Schizophrenia

  • 58
    Klampfl, K.; Taurines, R.; Preuss, A.; Burger, R.; Rothenhöfer, S.; Wewetzer, Ch.; Pfuhlmann, B.; Fegert, J.; Gerlach, M.; Mehler-Wex, C.:

    Serum Concentrations, Therapeutic Response and Side Effects in Children and Adolescents with Impulsive-Aggressive Symptoms during Risperidone Therapy

  • 66
    Girardi, P.; Serafini, G.; Pompili, M.; Innamorati, M.; Tatarelli, R.; Baldessarini, R. J.:

    Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

  • 73
    Schmauß, M.; Diekamp, B.; Gerwe, M.; Schreiner, A.; Ibach, B.:

    Does Oral Antipsychotic Pre-Treatment Influence Outcome of a Switch to Long-Acting Injectable Risperidone in Patients with Schizophrenia?